Nurix Therapeutics (NRIX) Amortization of Deferred Charges (2021 - 2026)

Nurix Therapeutics (NRIX) has 6 years of Amortization of Deferred Charges data on file, last reported at $1.6 million in Q2 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 44.13% year-over-year to $1.6 million in Q2 2026; TTM through May 2026 was $8.7 million, a 6.38% increase from a year earlier, with the FY2025 full-year figure at $10.1 million, up 42.28% from the prior year.
• Amortization of Deferred Charges for Q2 2026 stood at $1.6 million, up from $1.6 million in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for NRIX reached as high as $3.0 million in Q3 2025 and fell as low as $1.3 million in Q1 2022.
• Historically, Amortization of Deferred Charges has averaged $1.8 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Amortization of Deferred Charges surged 70.08% in 2022 and tumbled 44.13% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.4 million in 2022, then rose by 28.56% to $1.8 million in 2023, then slipped by 3.78% to $1.8 million in 2024, then soared by 43.16% to $2.5 million in 2025, then plunged by 36.48% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $1.6 million in Q2 2026, $1.6 million in Q1 2026, and $2.5 million in Q4 2025.